BACKGROUND: Analysis of prognostic factors in patients with metastatic breast cancer treated with epirubicin-based chemotherapy. PATIENTS AND METHODS: Data from 469 patients treated with epirubicin-based chemotherapy for metastatic breast cancer were used. Prognostic factors were identified (Cox multivariate analysis). A prognostic index was compiled and risk groups were established accordingly. The applicability of the index was investigated in a series of 116 patients. RESULTS: The prognostic factors identified were: liver, pleural, soft tissue, lung and bone metastases, performance status > 2, advancing age, abnormal elevation of serum lactate dehydrogenase and negative/unknown oestrogen receptor status. Four risk groups were established: good, intermediate I, intermediate II and poor. The median and five-year survivals in percentage were: good: 34 months (26%); intermediate I: 19 months (6%), intermediate II: 12 months (0%); poor: 7 months (1%). The corresponding values in the applicability group were: 32 months (23%); 28 months (22%); 18 months (5%); and 6 months (0%). CONCLUSIONS: It is more the number and impact on the organs involved, that predict the patients' survival. The construction of a prognostic index could be helpful in assessing the outlook for patients, especially the quite dramatic difference in long-term survival between the good and poor risk patients.
BACKGROUND: Analysis of prognostic factors in patients with metastatic breast cancer treated with epirubicin-based chemotherapy. PATIENTS AND METHODS: Data from 469 patients treated with epirubicin-based chemotherapy for metastatic breast cancer were used. Prognostic factors were identified (Cox multivariate analysis). A prognostic index was compiled and risk groups were established accordingly. The applicability of the index was investigated in a series of 116 patients. RESULTS: The prognostic factors identified were: liver, pleural, soft tissue, lung and bone metastases, performance status > 2, advancing age, abnormal elevation of serum lactate dehydrogenase and negative/unknown oestrogen receptor status. Four risk groups were established: good, intermediate I, intermediate II and poor. The median and five-year survivals in percentage were: good: 34 months (26%); intermediate I: 19 months (6%), intermediate II: 12 months (0%); poor: 7 months (1%). The corresponding values in the applicability group were: 32 months (23%); 28 months (22%); 18 months (5%); and 6 months (0%). CONCLUSIONS: It is more the number and impact on the organs involved, that predict the patients' survival. The construction of a prognostic index could be helpful in assessing the outlook for patients, especially the quite dramatic difference in long-term survival between the good and poor risk patients.
Authors: Gloria Bonuccelli; Aristotelis Tsirigos; Diana Whitaker-Menezes; Stephanos Pavlides; Richard G Pestell; Barbara Chiavarina; Philippe G Frank; Neal Flomenberg; Anthony Howell; Ubaldo E Martinez-Outschoorn; Federica Sotgia; Michael P Lisanti Journal: Cell Cycle Date: 2010-09-21 Impact factor: 4.534
Authors: Chantal Quinten; John Maringwa; Carolyn C Gotay; Francesca Martinelli; Corneel Coens; Bryce B Reeve; Henning Flechtner; Eva Greimel; Madeleine King; David Osoba; Charles Cleeland; Jolie Ringash; Joseph Schmucker-Von Koch; Martin J B Taphoorn; Joachim Weis; Andrew Bottomley Journal: J Natl Cancer Inst Date: 2011-12-07 Impact factor: 13.506
Authors: Kristoffer B Kristensen; Ida Marie Nedergaard Thomsen; Tobias Berg; Annette R Kodahl; Anders Bonde Jensen Journal: Breast Cancer Res Treat Date: 2021-04-10 Impact factor: 4.872
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: Klaartje Manders; Lonneke V van de Poll-Franse; Geert-Jan Creemers; Gerard Vreugdenhil; Maurice J C van der Sangen; Grard A P Nieuwenhuijzen; Rudi M H Roumen; Adri C Voogd Journal: BMC Cancer Date: 2006-07-06 Impact factor: 4.430
Authors: M I Koukourakis; A Giatromanolaki; E Sivridis; G Bougioukas; V Didilis; K C Gatter; A L Harris Journal: Br J Cancer Date: 2003-09-01 Impact factor: 7.640
Authors: Hui Miao; Mikael Hartman; Nirmala Bhoo-Pathy; Soo-Chin Lee; Nur Aishah Taib; Ern-Yu Tan; Patrick Chan; Karel G M Moons; Hoong-Seam Wong; Jeremy Goh; Siti Mastura Rahim; Cheng-Har Yip; Helena M Verkooijen Journal: PLoS One Date: 2014-04-02 Impact factor: 3.240